Results 31 to 40 of about 591,468 (262)

Real‐World Pediatric Blinatumomab Administration: Access to Outpatient Care Delivery and Impact of a Hospital‐Dispensed Model

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab has been shown to be highly effective for patients with pediatric B‐ALL and has recently become standard of care therapy. Due to its past use in the clinical trial setting, there is limited information available about real‐world administration.
Katelyn Oranges, Kelly A. Duffy, Sara McDonough, Evelyn Kurpiewski, R. Jennifer Randall, Allison Barz Leahy, Haley M. Newman, Joyce P. Lee, Stephen P. Hunger, Anne F. Reilly, David T. Teachey, Susan R. Rheingold, Daniel J. Zheng   +12 more
wiley   +1 more source

Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia. [PDF]

, 2017
Acquired elliptocytosis is a known but rarely described abnormality in the myelodysplastic syndromes (MDS). Here we report the case of an elderly male who was admitted to the hospital with chest pain, dyspnea, and fatigue and was found to be anemic with ...
Dwyre, Denis M, Jonas, Brian A, Kjelland, Jacob D   +2 more
core   +2 more sources

Clinical Insights Into Hypercalcemia of Malignancy in Childhood

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Hypercalcemia of malignancy (HCM) is a rare but life‐threatening metabolic emergency in children that occurs in less than 1% of pediatric cancer cases, with a reported incidence ranging from 0.4% to 1.0% across different studies. While it is observed in 10%–20% of adult malignancies, pediatric HCM remains relatively uncommon.
Hüseyin Anıl Korkmaz
wiley   +1 more source

GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. [PDF]

, 2019
We report graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) (a composite end point of survival without grade III-IV acute GVHD [aGVHD], systemic therapy-requiring chronic GVHD [cGVHD], or relapse) and cGVHD-free relapse-free survival ...
Abdel-Azim, Hisham, Ahmed, Ibrahim, Aljurf, Mahmoud, Alousi, Amin M., Arora, Mukta, Askar, Medhat, Auletta, Jeffery J., Bhatt, Vijaya, Bredeson, Christopher, Chhabra, Saurabh, Couriel, Daniel R., Diaz, Miguel Angel, Gadalla, Shahinaz, Gajewski, James, Gale, Robert Peter, Gergis, Usama, Hematti, Peiman, Hemmer, Michael T., Hildebrandt, Gerhard C., Holtan, Shernan G, Inamoto, Yoshihiro, Khandelwal, Pooja, Kitko, Carrie, MacMillan, Margaret L., Majhail, Navneet, Marks, David I., Mehta, Parinda, Mehta, Rohtesh S., Nishihori, Taiga, Olsson, Richard F., Pawarode, Attaphol, Pidala, Joseph, Prestidge, Tim, Qayed, Muna, Rangarajan, Hemalatha, Ringden, Olle, Saad, Ayman, Savani, Bipin N., Schultz, Kirk R., Seo, Sachiko, Shah, Ami, Shah, Niketa, Solh, Melhem, Spellman, Stephen R., Spitzer, Thomas, Szer, Jeffrey, Teshima, Takanori, Verdonck, Leo F, Wagner, John, Wang, Tao, Weisdorf, Daniel J., Williams, Kirsten M., Wirk, Baldeep, Yared, Jean A.   +53 more
core   +2 more sources

Survival Outcomes and Complications Among Canadian Children With Retinoblastoma: A Population‐Based Report From CYP‐C

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Retinoblastoma (RB) is the most common pediatric ocular cancer, yet population‐based data on survival and risk factors remain limited. This study aimed to describe survival in a large national RB cohort and identify predictors of death and complications.
Samuel Sassine, Ofélie Trudeau‐Ferrin, Caroline Laverdière, Patrick Hamel, Rosanne Superstein, Bénédicte Koukoui, Carole Provost, Paul C. Nathan, Vijay Ramaswamy, Furqan Shaikh, Brenda Gallie, Ashwin Mallipatna, Stephanie Kletke, Helen Dimaras, Hallie Coltin   +14 more
wiley   +1 more source

216 Jewish Hospital of St. Louis [PDF]

, 1984
https://digitalcommons.wustl.edu/bjc_216/1170/thumbnail ...

core   +1 more source

Exertional sickling: Questions and controversy [PDF]

, 2014
Sickle cell trait (SCT) occurs in about 8% of African-Americans and is often described to be of little clinical consequence. Over time, a number of risks have emerged, and among these are rare but catastrophic episodes of sudden death in athletes and ...
Blinder, Morey A., Russel, Sarah
core   +3 more sources

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács, Zoltán Köllő, Balázs Gellért Karvaly, Mahmoud Obeidat, Rita Nagy, Péter Hegyi, Brigitta Teutsch, Eszter Tuboly, Miklós Garami   +8 more
wiley   +1 more source

Patient/Family Education for Newly Diagnosed Pediatric Oncology Patients [PDF]

, 2016
There is a paucity of data to support evidence-based practices in the provision of patient/family education in the context of a new childhood cancer diagnosis.
Ahern, JoAnn, Barakat, Lamia P., Bhatia, Smita, Bingen, Kristin M., Bondurant, Patricia G., Cohn, Susan L., Dobrozsi, Sarah K., Haugen, Maureen, Herring, Ruth Anne, Hockenberry, Marilyn, Hooke, Mary C., Landier, Wendy, Martin, Melissa, Murphy, Kathryn, Newman, Amy R., Rodgers, Cheryl C., Ruccione, Kathleen S., Sullivan, Jeneane, Weiss, Marianne E., Withycombe, Janice, Yasui, Lise   +20 more
core   +1 more source

Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study [PDF]

, 2019
Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with ...
Accurso V., Casimiro P., Contrino A. D., Di Piazza F., Perez A., Raso S., Russo A., Santoro M., Siragusa S.   +8 more
core   +1 more source